The CPAC Lab, led by Angela Kashuba, former dean of @UNCPharmacy, supports the global #HIV research community through expertise in pharmacology
Joined April 2020
- Tweets131
- Following175
- Followers278
- Likes114
We're headed to ASMS 2026, hope to see you there!
Register 👉 asms.org/conferences/annual-…
Abstract details below!
📈 Development and Validation of an LC-MS/MS Method for Quantification of Protein-Unbound Doravirine in Human Plasma using Rapid Equilibrium Dialysis, Abstract# 327669, presented by Amanda Schauer, Monday June 1
Our recent work was featured as a Clinical Research Update in HIV Specialist Magazine!!
💊 Engel N, et al. Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention. J Infect Dis. 2026 Feb 18;233(2):257-260. onlinedigeditions.com/public…
We supported 7 abstracts at CROI 2026!! Nathan Engel and Amanda Poliseno had great poster presentations, and our team posed with the Blue Blear in Denver, Colorado 😀
New @JIDJournal editorial favors pursuit of a clinical trial assessing on-demand #PrEP in women following our model-informed predictions of its efficacy for #HIVprevention
🔗 Editorial: academic.oup.com/jid/advance…
🔗 Original Publication: academic.oup.com/jid/advance…
Our research advocating for 2-1-1-1 on-demand PrEP for cisgender women was featured in @BodyPROHIV! Check out Mackenzie Cottrell's interview with commentary from Jenell Stewart @HennepinHC discussing this "exciting step in the right direction"
🔗thebodypro.com/hiv/on-demand…
New from our lab! Adding a 4th day to the on-demand PrEP regimen may boost HIV protection for cisgender women, according to new modeling research.
academic.oup.com/jid/advance…
#HIVPrevention #PrEP #WomensHealth #UNCPharmacy
🎉 Happy to share that Eli Rosen was awarded an R01!
This collaboration with OHSU will benchmark PK for both long-acting and daily ARVs in rhesus macaques and examine how pre-treatment immunopathogenic damage affects ARV tissue penetration
reporter.nih.gov/search/xxd0…
#HIVResearch
Our collaboration with University of Colorado compares direct vs. indirect DBS assays for HIV PrEP adherence. We offer guidance for clinical interpretation, including adjustments for sample degradation outside cold-chain.
🔗 doi.org/10.1093/jac/dkaf279
#HIVPrevention #PrEP
Antiretrovirals don’t reach all genital tissues equally—some areas may be underprotected. New imaging from a collaboration with our laboratory reveals why this matters for prevention and cure. #HIVresearch #ARVs #HIVprevention
pubmed-ncbi-nlm-nih-gov.libp…
New guidelines from a collaboration with our laboratory improve how we read PrEP drug levels in blood spots—helping ensure people get the protection they need. #HIVprevention #PrEP #Adherence
pubmed-ncbi-nlm-nih-gov.libp…
The HIV PDR is revolutionizing how HIV drug data is shared—making decades of research searchable, standardized, and ready to power the next breakthroughs in treatment and prevention. #HIVresearch #DataSharing
Check out our publication here 👉 doi-org.libproxy.lib.unc.edu…
#CROI2025 was fantastic! We are incredibly proud of Mackenzie Cottrell and her well-received oral presentation, "Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention", which is featured on NATAP!
natap.org/2025/CROI/croi_81.…
Check out our upcoming abstract presentation when you're at #ASCPT2025!!
A Modeling Approach to Expedite the Development of a New Long-Acting Controlled-Release Multipurpose Formulation Containing Medroxyprogesterone Acetate
We are authors on 8 abstracts at #CROI2025!! Titles for 3 oral 🎙️ and 5 poster 📊 presentations are below
📊Dose-Ranging Pharmacokinetics and Efficacy of a 90-Day Multipurpose IVR Delivering Islatravir
📊Effect of Antiretroviral Regimen on Contraceptive Failure Among Women Using Injectable Contraception